In a clinical trial called CHECKMATE-227, patients with metastatic or recurrent NSCLC were given Opdivo and Yervoy or platinum-doublet chemotherapy for up to 24 months. The overall survival in patients taking Yervoy and Opdivo was 15 to 20.1 (median 17.1) months compared to 12.7 to 16.7 (medi...